文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > 所有分类 > 医药卫生 > 基础医学 > GLP-1综述
侵权投诉

GLP-1综述

Therapeutic Advances in Endocrinology and Metabolism

GLP-1综述

Review

Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus

Kira B. Harris and Delilah J. McCarty

Ther Adv Endocrinol Metab

2015, Vol. 6(1) 3 –18DOI: 10.1177/

2042018814558242© The Author(s), 2014. Reprints and permissions: doc.guandang.net journalsPermissions.nav

Abstract: Glucagon-like peptide-1 (GLP-1) has been evaluated for use in the treatment of type 2 diabetes mellitus (T2DM) due to its role in glucose regulation. Four GLP-1 receptor agonists (RAs) are currently indicated for T2DM in the USA. Exenatide and liraglutide are short-acting and require twice-daily and daily dosing, respectively. Two longer acting agents, exenatide long-acting release (LAR) and albiglutide, were formulated to allow for once-weekly dosing. All four GLP-1 RAs have demonstrated reductions in hemoglobin A1c, fasting blood glucose, and body weight both as monotherapy and in combination with first- and second-line diabetes agents including metformin, sulfonylureas, thiazolidinediones, and insulin.

Greater glycemic control was seen with liraglutide compared with the other GLP-1 treatment options; however, the two long-acting agents were superior to exenatide twice daily. All agents were well tolerated with most adverse events being mild or moderate in nature. The most common adverse event was transient nausea which typically resolved 4–8 weeks after treatment initiation. Long-acting agents had lower rates of nausea but an increased incidence of injection site reactions. Trials have suggested GLP-1 RAs may improve cardiovascular risk factors including blood pressure, lipid parameters and inflammatory markers. Future trials are needed to confirm the clinical outcomes of these agents. Overall, GLP-1 RAs will provide benefit for patients with T2DM intolerable to or not reaching glycemic goals with first-line agents, especially in patients in need of weight loss.

Keywords: albiglutide, exenatide, exenatide long-acting release, GLP-1 RAs, liraglutide, type 2 diabetes mellitus

et al. 1999]. This glucose-dependent effect Correspondence to: Introduction

Kira B. Harris, PharmD,

Glucagon-like peptide 1 (GLP-1) is an endoge-reduces the risk of hypoglycemia.BCPS, CDE

Assistant Professor, nous hormone produced and released by intesti-Wingate University School

nal epithelial endocrine L cells in response to of Pharmacy, 515 North food intake [Holst, 2007; Frias and Edelman, The use of GLP-1 therapy was limited by its rapid Main Street, Wingate,

NC 28174, USA

2007; Nauck et al. 2004]. While the effects of breakdown by dipeptidyl peptidase IV (DPP-IV) k.brice@wingate.eduGLP-1, including increased insulin secretion, [Holst, 2006, 2007]. However, several GLP-1 Delilah J. McCarty, decreased glucagon secretion, slowed gastric receptor agonists have been discovered that are PharmD, CPP, BCACP,

CDE

emptying, and maintenance of blood glucose DPP-IV resistant, making them valuable in diabe-Wingate University School (BG) levels, are maintained, GLP-1 secretion is tes treatment. Exenatide and liraglutide were US of Pharmacy, Wingate,

NC, USA

GLP-1综述

often reduced in patients with type 2 diabetes Food and Drug Administration (FDA) approved mellitus (T2DM) [Holst, 2007; Frias and in 2005 and 2010 and are administered subcuta-Edelman, 2007; Nauck et al. 2004; Kreymann neously twice daily and daily, respectively [Amylin et al. 1987; Nauck et al. 1986]. When exogenous Pharmaceuticals, Inc., 2011; Novo Nordisk A/S, GLP-1 is administered to patients with T2DM, 2013]. In 2012 and 2014, exenatide long-acting fasting BG (FBG) is decreased while c-peptide release (LAR) and albiglutide were approved. and insulin secretion are increased until BG These agents were modified to increase the half returns to normal [Nauck et al. 1993; Toft-Nielsen life, allowing for once weekly subcutaneous

doc.guandang.net 3

第1页

你可能喜欢

热门文档

相关文档

  • GLP_1及其类似物的研究进展

    2011,Vol.17 No.8 Issue No.235 doi:10.3969/j.issn.1009-4393.2011.8.014 GLP-1及其类似物的研究进展李国慧 高如攀 综述 Summarize 多数2型糖尿病患者...

  • GLP-1类似物在2型糖尿病中的临床应用进展

    Chinese Journal of New Drugs 2013 , 22 ( 5 ) ·综述· GLP1 类似物在 2 型糖尿病中的临床应用进展 1, 2 1, 3 1 1 宋智慧 ,王璐, 纪立伟 ,胡...

  • GLP-1受体激动剂与DPP-4抑制剂大PK

    180 糖尿病天地?临床刊 2012年4月 第6卷 第4期 Diabetes World, Apr 2012,Vol 6, No.4 doi:10.3969/j.issn.1672-7851.2012.04.011 临床综述 GLP-1...

  • GLP_1与细胞凋亡的研究进展

    现将 GLP-1 与细 胞凋亡的研究进展综述如下。 钟成福养的乳鼠心肌细胞中研究发现, 与未 经过 GLP-1 预处理组相比 ,经过 GLP-1 预处理的缺氧 / 复氧心肌...

  • NHL2013092201 击糖尿病——GLP-1利拉鲁肽的基础与临床

    糖依赖 性胰岛索释放肽(glucose-dependentinsulinotropicpolypeptide, 文从基础和临床角度系统阐述GLP-1对糖尿病治疗的分子机 制,并对利拉鲁肽的临床研究结果进行综述。...

  • GLP-1类似物市场潜力与风险分析

    http://www.pharmadl.com 上海医药工业研究院信息中心 GLP-1 类似物新药临床疗效综述(二) 类似物新药临床疗效综述((Exenatide+ Liraglutide) )细胞功能——预防并...

  • GLP-1受体激动剂及DPP-Ⅳ抑制剂的研究进展

    ( DPP -? ) 抑制剂的研究进展进 行了 * 综述 。 介绍了 G LP -1 的血糖调控机制 , 还对 GLP -1 受体激动剂 ( 如 Ex endin-4 , Exentide LAR, ...

  • 胰升糖素样肽-1的研究进展

    GLP-1)具有强力的促胰岛素分泌作用,将成为2型糖尿病治疗的新方法,是目前胃肠道激素研究的一个新热点,现就GLP-1生化、生理及病理生理学等方面的研究进展综述如下...

  • 2011-10-9胆汁酸的综述

    2011-10-9胆汁酸的综述_医药卫生_专业资料。关于胆汁酸与血糖、血脂及能量代谢...细胞,这些细胞以 tgr5 依赖性的方式 来分泌肠源性的肠促胰岛素 GLP-1 的...

  • CRP综述1-2

    CRP综述1-2_医药卫生_专业资料。CRP综述一、CRP 综述 C-反应蛋白(CRP)是 1930 年由 Tillet 和 Francis 首先发现的,因为它能与肺炎链球菌荚膜 C 多 糖物质在...

站点地图 | 文档上传 | 侵权投诉 | 手机版
本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  -  email